[Bronchial smooth muscle mitochondria: A new target for asthma therapy?]

Rev Mal Respir. 2020 Mar;37(3):201-204. doi: 10.1016/j.rmr.2020.02.004. Epub 2020 Mar 2.
[Article in French]

Abstract

The main purpose of this review is to highlight mitochondria as a new therapeutic target to prevent bronchial smooth muscle (BSM) remodeling in asthma. Severe asthmatic patients, representing 5-10% of all asthmatics, are characterized by an increased BSM mass which is highly correlated with the severity of the disease and the rate of exacerbations. None of the current asthma therapies are effective in reducing BSM remodelling. This review, based on the current literature, reports the role of mitochondria in BSM, particularly in calcium signaling.

Keywords: Asthma; Asthme; Energetic metabolism; Mitochondria; Mitochondrie; Métabolisme énergétique.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Asthmatic Agents / administration & dosage
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / metabolism
  • Asthma / pathology
  • Bronchi* / cytology
  • Bronchi* / drug effects
  • Bronchi* / metabolism
  • Bronchi* / ultrastructure
  • Drug Delivery Systems / methods
  • Energy Metabolism / drug effects
  • Humans
  • Mitochondria, Muscle / drug effects*
  • Mitochondria, Muscle / metabolism
  • Molecular Targeted Therapy / methods*
  • Molecular Targeted Therapy / trends
  • Muscle, Smooth / cytology
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / ultrastructure
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / physiology
  • Therapies, Investigational / methods
  • Therapies, Investigational / trends

Substances

  • Anti-Asthmatic Agents